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Abstract
Background: Osteoarthritis (OA) is a multifactorial degenerative condition of the whole joint with a complex
pathogenesis whose development and progression is significantly mediated by interactions between the joint
cartilage and articular tissues, particularly, proinflammatory mediators and oxidative stress, which results in
cartilage deterioration and subchondral bone destruction. HIF-1 alpha regulates oxygen homeostasis in
hypoxic tissues such as joint cartilage; efficiency of transcriptional activity of the HIF1A gene is strongly
influenced by the presence of polymorphic variants. Given the loss of articular cartilage and with intention to
restore damaged tissue, WISP-1 participates in the development of subchondral bone; further, its expression is
highly increased in chondrocytes of OA patients. The aim of this study was to evaluate gene frequencies of
HIF1A and WISP1 polymorphisms in Mexican patients suffering from knee OA.
Methods: We determined HIF1A rs11549465 (P582S), rs11549467 (A588T), and rs2057482 (C191T), and WISP1
rs2929970 (A2364G) polymorphisms in 70 Mexican patients with knee OA and compare them to those
present in 66 ethnically matched healthy controls. Genotyping for these polymorphisms was performed by
Real-Time PCR using TaqMan probes.
Results: Gene frequencies exhibited a significant increase of the CC genotype of rs11549465 polymorphism in
knee OA patients as compared with those present in controls (P = 0.003 OR = 5.7, 95 % CI = 1.7–21.6); CT
genotype and T allele showed decreased frequency in the knee OA group vs. the controls (P = 0.003 OR = 0.2,
CI = 0.05–0.6; and P = 0.004 OR = 0.2, CI = 0.05–0.65, respectively). Allele frequencies of the other polymorphic
variants were similar in both patients and controls.
Conclusions: These results suggest that the presence of the rs11549465 SNP (HIF1A) plays a role protective in
the loss of articular cartilage in our population, and offers the possibility to further study the molecular
mechanisms within cartilage and subchondral bone.
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Background
Osteoarthritis (OA) is one of the most common rheum-
atic disorders; it is characterized by joint disease whose
cause is not completely understood. OA has a complex
pathogenesis due to the interaction of genetic, mechan-
ical, biochemical, metabolic, endocrine, and environ-
mental factors that result in cartilage breakdown and
diverse changes in subchondral bone, which may lead to
chronic pain, joint swelling, deformity and whole joint
abnormalities resulting in disability [1–3]. This process
entails the formation of bony outgrowths (osteophytes) and
inflammation of the synovial membrane, thus triggering
catabolic and proinflammatory mediators such as cytokines,
prostaglandin E2, neuropeptides and nitric oxide [4–7].
Worldwide estimates indicate that 9.6 % of men and 18 %
of women ≥ 60 years have symptomatic OA [8–11].
Through inflammatory mediators, biochemical injury
and oxidative stress, viability of chondrocytes is compro-
mised. Increased oxidative stress in articular cartilage
has been the target of molecular research and thera-
peutic intervention [12–14]. Healthy articular cartilage is
typically an avascular tissue, the oxygen tension ranges
from 0.5 to 10 % [12]. Therefore, in order to maintain
oxygen homeostasis in chondrocytes and cartilage,
hypoxia-inducible factor-1 alpha (HIF-1α) is necessary
to survive extremely low oxygen tensions. [12, 15, 16].
Furthermore, this transcriptional factor also has a role in
the regulation of glucose transport, anaerobic energy
generation and matrix synthesis by articular chondro-
cytes. The active site of this protein is an oxygen-
dependent degradation domain (ODDD) that functions
as an oxygen sensor [17, 18].
In the presence of normal oxygen tension levels, HIF-
1α is hydroxylated in a proline residue within ODDD; it
subsequently binds to ubiquitin and is degraded in the
proteasome [17–19]. However, under hypoxic condi-
tions, hydroxylation is inhibited and HIF-1α accumulates
in the cytoplasm, is phosphorylated and translocates to
the nucleus in order to activate transcription of its target
genes [18–22]. Some of these target genes include nitric
oxide synthase 2 (NOS2), vascular endothelial growth
factor (VEGF), erythropoietin (EPO), some glucose
transporters (GLUT1, GLUT3), Insulin-like growth fac-
tor type 2 (IGF2), which potentially acts in order to
maintain the chondroprotective functions challenged by
the detrimental conditions occurring in the OA joint en-
vironment [16, 20–25]. This relationship among differ-
ent genes renders the close relation of HIF-1α with
several pathologies [26–31].
It have been described polymorphic variants within
the HIF1A gene; for example, the rs11549465 (P582S),
and rs11549467(A588T) single-nucleotide polymorphisms
(SNPs) are located in exon 12, on 14th chromosome
and influence the transcriptional activity of this gene
to increase dramatically in comparison with the com-
mon isoform [32, 33].
Due to loss of articular cartilage and with the intention
to restore damaged tissue, WNT inducible signaling path-
way protein-1 (WISP-1) participates in the development of
subchondral bone. This protein plays an important role in
the formation, differentiation, growth, and maintenance of
bone and articular cartilage. Active Wnt signaling contrib-
utes to osteophyte formation and might play an essential
role in the anabolic pattern of joint remodeling observed
in ankylosing spondylitis and OA [34]. Furthermore, it has
also been showed that in both OA patients and experi-
mental models that there is an important increase in the
Wnt signaling pathway and over expression of the WISP1
gene [35–38]. Likewise, it was discovered that variant
rs2929970 (A2364G) of the WISP1 gene (located within of
the 8th chromosome) is related with the development of
spinal OA in postmenopausal women [39].
Because of the genetic variability of OA, the aim of
this study was to analyze rs11549465, rs11549467 and
rs2057482 SNPs of the HIF1A gene, and rs2929970




This study meets all criteria contained in the Declaration of
Helsinki and was approved by the Ethics and Research
Committee of the Instituto Nacional de Rehabilitación
(INR) (Ref. INR-18/13). All participants signed an informed
consent letter that included questions regarding age, gen-
der, weight, Body mass index (BMI), and birth origin. All
participants were >40 years, and declared to be native to
the central region of Mexico, and to have parents and
grandparents born in the same geographical region.
A total of seventy patients diagnosed with primary
knee OA, and sixty-six age-matched healthy controls
without symptoms or signs of OA, other types of arth-
ritis, or any joint diseases were recruited in this study.
The diagnosis of knee OA was based on the criteria of
the American College of Rheumatology [40], which in-
cluded primary OA with any symptoms and radio-
graphic signs of OA according to the Kellgren-Lawrence
(K&L) scale (≥2 scale). The clinical examination and
radiological assessment were performed by two inde-
pendent examiners who were blinded to the clinical
information. The control subjects were consecutively
selected among individuals without a personal and fam-
ily history of OA; asymptomatic healthy subjects sex and
age matched were include as control group. Other eti-
ologies causing knee diseases such as inflammatory arth-
ritis (rheumatoid, polyarthritic or autoimmune disease),
posttraumatic or post septic arthritis, skeletal dysplasia
or developmental dysplasia were also excluded.
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Sample collection
Peripheral blood samples were extracted by venipuncture
from each study participant to obtain blood serum for the
study of biochemical parameters, and EDTA tubes for iso-
lating DNA.
Determination of biochemical parameters
After collection of blood samples, the serum was sepa-
rated and maintained at −80 °C until use. For determin-
ation of glucose, total cholesterol, and uric acid levels in
both study groups, we employed a commercial kit (Diag-
nostic Systems, Germany). Quantification was performed
in by spectrophotometry (iMark™, BioRad).
Obtaining genomic DNA
Genomic DNA was extracted from 200 μL of whole blood
with the commercial QIAamp® DNA Blood Mini Kit,
QIAGEN (Hilden, Germany), following all of the supplier’s
instructions. DNA concentration was determined by spec-
trophotometry (NanoDrop 2000, Thermo Scientific), and
was of ~40 ng/μL.
Selection of HIF1A and WISP1 SNPs and Genotyping
Selection of SNP in HIF1A and WISP1 genes was con-
ducted based on information from the dbSNP database
(http://www.ncbi.nlm.nih.gov/projects/SNP/). Three poly-
morphisms were included for the HIF1A gene and one for
the WISP1 gene in the genotyping tests (Table 1). Real-
time PCR was performed in a total volume of 10 μL, that
contained 40 ng DNA (1 μL), 1X TaqMan Universal PCR
Master Mix (5 μL), TaqMan Probes 20X (0.5 μL), and
water (3.5 μL). Thermal cycling conditions were as fol-
lows: 95 °C for 10 min, followed by 40 cycles at 92 °C for
15 s and at 60 °C for 1 min. The Rotor-Gene Q Real-time
PCR System (QIAGEN, Hilden, Germany) was employed
for data acquisition. Genotyping of the HIF1A and WISP1
polymorphisms were carried out using the 5′ exonuclease
TaqMan Allelic Discrimination assay, which was per-
formed utilizing minor groove binder probes fluorescently
labeled with VIC or FAM and the protocol recommended
by the supplier (Applied Biosystems, Foster City, CA,
USA). Analysis for interpretation was performed with
Rotor-Gene Q Series ver. 2.0.2 software.
Statistical analysis
The demographic and clinical data were presented as
Mean ± SD and compared between groups by the Stu-
dent’s t-test. Multivariate logistic regression was used to
estimate odds ratios (ORs) and 95 % confidence intervals
(CI) after adjustment for age, gender, BMI, glucose, total
cholesterol, and uric acid, by using STATA ver. 12 soft-
ware. The genotype and allelic frequencies were evaluated
by Hardy-Weinberg equilibrium (HWE) and compared by
the Chi-square test and Fisher’s exact test by using an
online calculator tool (http://www.oege.org/software/
hardy-weinberg.html). Allelic and gene frequencies of
the HIF1A and WISP1 genes from both study groups were
calculated by direct count. P values < 0.05 were considered
statistically significant. For estimating risks, we employed
OR with a 95 % CI. These calculations were performed
using the EpiInfo statistical program (ver. 6, Centers for
Disease Control and Prevention, Atlanta, GA, USA).
Results
The demographical variables age, gender, weight, BMI,
glucose, total cholesterol, and uric acid of our study pop-
ulations are depicted in Table 2. Cases were older than
controls (P < 0.00001, 55.8 ± 6.7 vs. 47.5 ± 6.6, respect-
ively). The mean BMI of the OA group (29.8 ± 5.1) was
significantly higher than the control group (26.9 ± 4.6)
(P = 0.0007), similar with the previous studies that re-
ported high BMI increased the risk of developing OA.
None of the individuals belonging to the control group
had a BMI characteristic of obesity.
Serum levels of glucose and total cholesterol in both
groups were similar in patients and controls. Mean values
uric acid, were lower in the group of patients with OA as
compared to those present in the control group (P = 0.03,
5.48 ± 1.18 vs. 6.28 ± 2.2, respectively). According to radio-
logical KL classification, 62 patients were grade 2 and
eight were grade 4.
Table 1 Single-nucleotide polymorphism (SNP) studied
Gene Chromosome
position
dbSNP rs ID Location SNP type
HIF1A Chr14: 62207557 rs11549465 Exon 12 Pro582Ser, C1772T
Chr14: 62207575 rs11549467 Exon 12 Ala588Thr, G1790A
Chr14: 62213848 rs2057482 3′ UTR C191T
WISP1 Chr8: 134229883 rs2929970 3′ UTR A2364G
Table 2 Demographic, anthropometric and biochemical
parameters of knee OA patients and control group





Male/Female (%) 11.4/88.5 10.6/89.4 0.87
Age (years) 55.8 ± 6.7 47.5 ± 6.6 < 0.00001
Weight (kg) 72.3 ± 14.5 68.8 ± 13.4 0.14
BMI (kg/m2) 29.8 ± 5.1 26.9 ± 4.6 0.0007
Glucose (mg/dL) 112.4 ± 43.4 102.4 ± 77.9 0.36
Total cholesterol (mg/dL) 203.0 ± 31.3 206.1 ± 60.3 0.74
Uric acid (mg/dL) 5.48 ± 1.18 6.28 ± 2.2 0.03
Data are expressed as means ± Standard deviation. P values were estimated
using Student t test, α = 0.05. BMI Body-mass index = normal: 18.5–24.9;
overweight: 25.0–29.9; obesity: ≥ 30.0. Normal values for glucose: 75–110 mg/dL;
total cholesterol: <200 mg/dL; uric acid: 3.5–6.7 mg/dL. Significant P values are
reported in bold
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The HWE demonstrated no differences in the distribu-
tion of all polymorphisms studied in both groups
(Table 3). Table 4 shows the gene and allele frequencies
of the polymorphisms studied in patients in comparison
with the control group. Only rs11549465 polymorphism
of the HIF1A gene was found to be significantly associ-
ated with increased risk of OA. The OA group exhibited
an increased frequency of the CC genotype and the C
allele in comparison with the control group (P = 0.003,
94.2 vs. 74.2 %, OR = 5.7, 95 % CI = 1.7–21.6; and P =
0.004, 97.0 vs. 87.1 %, OR = 5.03, 95 % CI = 1.53–18.2,
respectively). For the same polymorphism, CT genotype
and the T allele frequencies were higher in the control
group in comparison with the knee OA group (P =
0.003, 25.8 vs. 5.8 %, OR = 0.2, 95 % CI = 0.05–0.60; and
P = 0.004, 12.9 vs. 3.0 %, OR = 0.2, 95 % CI = 0.05–0.65,
respectively). Distribution of rs11549467 and rs2057482
polymorphisms of the HIF1A gene and the rs2929970
polymorphism of the WISP1 gene in both study groups
were statistically nonsignificant.
After adjustment of age, gender, weight, BMI, glucose,
total cholesterol, and uric acid, no statistically significant
associations with OA were found. Additionally, we inves-
tigate the relationship between the radiological grade of
OA and the rs11549465 polymorphism showing that the
grade 2 maintains a relationship with the polymorphism
(CC genotype: P = 0.009, OR = 5.0; C allele: P = 0.01, OR =
4.4; CT genotype: P = 0.009, OR = 0.2; T allele: P = 0.01,
OR = 0.2); whereas the grade 4 did not showed any rela-
tionship (Additional file 1).
Discussion
As is the case of other ethnic groups, OA is the most
common human arthritis in Mexicans [10], its incidence
is increasing due to the current pandemic of overweight
and obesity in this ethnic group. Several risk factors have
been described for the development, progression and se-
verity of OA; however, at present it is not possible to ex-
plain interindividual variability in destruction of joint
cartilage. We studied Mexican patients with knee OA,
some SNP in HIF1A and WISP1 genes related with oxygen
homeostasis in joint cartilage and bone development, and
their relationship with biochemical parameters.
Our results show that the BMI in the patients with
OA was higher with respect the healthy control group.
This is in line with previous studies that reported how a
higher BMI is a risk factor for developing knee OA,
probably induced by the biomechanical joint stress [41].
Interestingly, our results showed a significant decreased
level of uric acid in the OA patients with respect the
healthy control. This is in line with the study of Mishra
et al. [42], who attributed this phenomenon to the anti-
oxidant properties of uric acid since they found an inverse
correlation between uric acid and the presence of malon-
dialdehyde (pro-oxidant agent). This induces to consider a
possible link between the reduction of both the content
Table 3 Distribution of polymorphisms in patients and controls
SNP Genotype HWE (P)
Patients Controls Patients Controls
rs11549465 CC CT TT CC CT TT
66 4 0 49 17 0 0.8056 0.2297
rs11549467 GG GA AA GG GA AA
68 2 0 65 1 0 0.9034 0.9505
rs2057482 TT TC CC TT TC CC
59 11 0 55 11 0 0.4755 0.4601
rs2929970 GG AG AA GG AG AA
25 37 8 24 33 9 0.3018 0.6581
HWE Hardy-Weinberg equilibrium. If P < 0.05, not consistent with HWE
Table 4 Gene and allele frequencies of the polymorphisms
studied in knee OA patients and controls
SNP OA Controls P value* OR (95 % CI)
N (%) N (%)
HIF1A (rs11549465)
CC 66 (94.2) 49 (74.2) 0.003 5.7 1.7–21.6
CT 4 (5.8) 17 (25.8) 0.003 0.2 0.05–0.60
TT 0 (0.0) 0 (0.0) -
C 136 (97.0) 115 (87.1) 0.004 5.0 1.53–18.2
T 4 (3.0) 17 (12.9) 0.004 0.2 0.05–0.65
HIF1A (rs11549467)
GG 68 (97.1) 65 (98.5) 1.77 0.5 0.02–76.1
GA 2 (2.8) 1 (1.5) 1.77 1.9 0.13–54.6
AA 0 (0.0) 0 (0.0) -
A 138 (98.5) 131 (99.2) 1.18 0.5 0.02–7.5
G 2 (1.5) 1 (0.8) 1.18 1.9 0.13–53.5
HIF1A (rs2057482)
TT 59 (84.3) 55 (83.3) 2.64 1.0 0.39–2.93
TC 11 (15.7) 11 (16.4) 2.64 0.9 0.34–2.54
CC 0 (0.0) 0 (0.0) -
T 129 (92.1) 121 (91.6) 1.76 1.0 0.41–2.76
C 11 (7.9) 11 (8.4) 1.76 0.9 0.36–2.43
WISP1 (rs2929970)
GG 25 (35.7) 24 (36.4) 2.52 0.9 0.42–2.06
AG 37 (52.8) 33 (50.0) 2.52 1.0 0.49–2.39
AA 8 (11.5) 9 (13.6) 1.98 0.7 0.24–2.58
A 53 (37.8) 51 (38.6) 1.78 0.9 0.58–1.63
G 87 (62.2) 81 (61.4) 1.78 1.0 0.62–1.74
OA Patients with knee osteoarthritis, OR Odds ratio, CI Confidence interval;
*P value corrected by Bonferroni test, <0.05. Significant P values and OR are
reported in bold
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and the antioxidant property of uric acid and the inflam-
matory process of OA.
Regarding the analysis of polymorphic variants of HIF1A,
we found that the rs11549465 SNP located in the exon
12 within the HIF1A gene was associated in Mexican pa-
tients with knee OA. Our results show that the presence
of the CC homozygous variant or C allele represent po-
tential risk factors for development of knee OA; contrar-
ily, we detected that the heterozygous variant of CT or T
allele of the rs11549465 polymorphism of the HIF1A
gene (in comparison with the homozygous carriers) play
a protector role against the disease. This phenomenon
may be explained by the fact that the presence of this
polymorphism confers greater stability to the HIF-1α
protein, as demonstrated by Tanimoto et al. [22]. In their
study it has been demonstrated that the substitution of
proline by serine in the 582 (P582S) position enhances
its transcriptional activity due to an alteration in the
characteristics and properties of the binding sites with
the target genes [43]. This permit supposes a beneficial
effect in maintaining cartilage homeostasis and therefore
avoiding joint damage. A similar phenomenon was also
obtained in other immunological disease such as type 2
diabetes mellitus [23].
Additionally, endochondral ossification process is
triggered by the development of osteophytes. WISP-1
is an osteogenic factor and an osteoblast differenti-
ation factor that has been studied in OA models, in
which an increase in its expression was reported [32, 33].
WISP-1 is a member of the CCN family of connect-
ive tissue growth factors, which also includes WISP-2
and WISP-3. Members of the CCN family have been
implicated in developmental processes such as chon-
drogenesis, osteogenesis, and angiogenesis. French
et al. [44] could show that WISP-1 functions as osteo-
genesis potentiating factor promoting mesenchymal
cell proliferation while repressing chondrocytic differ-
entiation in vitro. This would suggest that the CCN
family play a critical role in cartilage homeostasis.
Urano et al. [39] analyzed the rs2929970 (A2364G) 3′
UTR polymorphism in Japanese women with vertebral
OA, demonstrating an increase in the GG genotype in
the sub-group with end-plate sclerosis. This poly-
morphism is located in the 3′ untranslated region,
within a region of splicing variation, and it may influ-
ence messenger RNA stability, translational efficiency
or gene expression, and subsequently contribute to the
risk of OA. Under the same context, and based on the
frequency of polymorphism in our population, we decided
use the same variant of the WISP1 gene in Mexican pa-
tients with knee OA, but in our study we did not find any
association. Whatsoever, it is possible that the evaluated
polymorphism, do not play a major role in the develop-
ment of knee OA in our population, so interesting it
would be to explore other polymorphic sites within the
WISP1 gene. It will be important to replicate this study in
distinct ethnic groups to better understand the mecha-
nisms whereby gene interacts with environmental factors
to develop OA.
We are aware that a larger cohort of patients is
needed in order to strengthen the statistical power of
results, and this aspect is the main limitation of our
study. However we believe that our preliminary re-
sults could be of interest since that there are no pa-
pers focused in this topic, especially involving a
population with particular genotype such as Mexican
population, and could differ from that typically is re-
ported in other populations. Further investigation in-
volving large cohort of patients and different centers
could support better these preliminary results.
Conclusions
In conclusion, our results suggest that the presence of
the rs11549465 SNP (HIF1A) plays a role protective in
the loss of articular cartilage in our population, and of-
fers the possibility to further study the molecular mecha-
nisms within cartilage and subchondral bone. Thus,
HIF-1α would be a useful molecular tool for the devel-
opment of new diagnostic markers, as well as of thera-
peutic target in OA.
Additional file
Additional file 1: Gene and allele frequencies of the rs11549465
polymorphism in OA patients according the Kellgren-Lawrence
scale. (DOC 42 kb)
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